DA Davidson analyst Thomas Diffely lowered his price target on Teradyne to $35 and kept his Neutral rating. The analyst notes that while Q3 earnings topped consensus and Q4 guidance was better than expected, he is concerned with the slowing sales in China on rising geopolitical tensions. Diffely adds that despite the outperformance in Teradyne's core business, he is also cautious on the international sales prospects for its Universal Robots products.
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSImpinj (PI) up... To see the rest of the story go to thefly.com. See Story Here